Olema Oncology (OLMA) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
10 Nov, 2026Executive summary
Clinical-stage pipeline centered on palazestrant and OP-3136; no approved products or product-sales revenue, with losses expected to continue as clinical development expands.
Palazestrant is being developed as monotherapy and in combinations for metastatic breast cancer; OP-3136 is advancing in clinical development.
OPERA-01 Phase 3 top-line results are expected in Q1 2027; OPERA-02 enrollment is accelerating.
Q3 net loss was $73.6M versus $42.2M a year earlier; cash, cash equivalents and marketable securities totaled $413.8M at quarter-end.
Financial highlights
Q3 operating expenses rose 69% YoY to $77.5M; operating loss was $77.5M versus $45.9M, and net loss was $73.6M versus $42.2M.
Q3 GAAP R&D expense increased to $67.6M from $40.0M; non-GAAP R&D, excluding stock-based compensation, was $59.9M versus $37.4M.
Q3 GAAP G&A expense increased to $9.9M from $5.9M; non-GAAP G&A, excluding stock-based compensation, was $5.5M versus $4.3M.
9M net loss widened to $189.9M from $116.4M; operating expenses reached $202.7M, up 58% YoY.
Q3 interest income was $4.1M and total other income was $3.9M, partially offsetting operating loss.
Outlook and guidance
Cash, cash equivalents, marketable securities and available Credit Facility balance are expected to fund the current operating plan through mid-2028; runway depends on assumptions and may be shorter.
OPERA-01 top-line results are expected in Q1 2027; an NDA submission is planned for 2027 and potential U.S. approval and launch in 2028, if successful.
Initial palazestrant-atirmociclib and palazestrant-everolimus data, and initial OP-3136 plus fulvestrant data, are expected at SABCS in December 2026.
Enrollment in the OP-3136 plus darolutamide Phase 1b/2 mCRPC study with Bayer is planned for Q4 2026; additional combination data are expected in mid-2027.
Latest events from Olema Oncology
- Q1 OPERA-01 data will shape a potential mid-2028 launch and broader treatment opportunity.OLMA
Stifel 2026 Healthcare Conference 2026 - OPERA-01 data in Q1 2027 will test palazestrant across both ESR1 subsets.OLMA
3rd Annual Guggenheim Healthcare Innovation Conference - Phase III breast cancer trial readout for palazestrant expected Q1 2027; new combo data due next year.OLMA
H.C. Wainwright 28th Annual Global Investment Conference - Palazestrant and KAT6 programs offer strong differentiation and major market potential, with key data ahead.OLMA
Morgan Stanley 24th Annual Global Healthcare Conference - Phase III breast cancer trials for palazestrant target major markets, with key data due in Q1 2027.OLMA
Citigroup’s Biopharma Back to School Summit 2026 - Net loss rose 44% to $63.2M in Q2 2026 as Phase 3 trial enrollment completed and cash reached $461M.OLMA
Q2 2026 - Pivotal trials and new combinations position the pipeline for major advances in breast cancer care.OLMA
Jefferies London Healthcare Conference 2025 - Phase III breast cancer data expected in fall; KAT6 combos and strong cash position support growth.OLMA
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Promising clinical progress and strategic trial updates position the pipeline for significant impact.OLMA
Jefferies Global Healthcare Conference 2026